

CURRICULUM VITAE

Name:

Madhav Thambisetty

Business Contact Information:

Senior Investigator and Chief (Series-0602; Title-42) Clinical and Translational Neuroscience Section Laboratory of Behavioral Neuroscience, National Institute on Aging (NIA) National Institutes of Health (NIH)

Web of Science Researcher ID:

P-5720-2018

Google Scholar h-index: 49, total citations: 8420 (as of 05/05/2022)

Education:

- Fellow and Clinical Associate in Cognitive Neurology and Sleep Disorders, Emory University School of Medicine, Atlanta: December 1st 2002-November 30th 2003
- Resident in Neurology: Emory University School of Medicine, Atlanta: December 1st 1999-November 30th 2002
- Resident in Internal Medicine: Emory University School of Medicine, Atlanta: December 1st 1998-November 30th 1999
- DPhil (Doctor of Philosophy) in Clinical Pharmacology ('Studies on the neurotrophic effects of chronic electroconvulsive shock and 5-HT in the adult rat brain') (thesis supervisor: Prof. David Grahame-Smith) University of Oxford, Green College: 1995-1999, degree awarded 27th November 1999
- Bachelor of Medicine and Surgery (MBBS) Government Medical College, University of Calicut, India: 1988-1994, degree awarded 20th November 1995

Board Certification and medical licenses held:

- Board certification in Neurology: Diplomate of the American Board of Psychiatry and Neurology (ABPN), certificate number 52853, July 2004, Re-certified in 2015
- Maryland Board of Physicians, D68423; 2009-current
- Specialist registration in Neurology, General Medical Council, UK; 2008
- Certified, Educational Commission for Foreign Medical Graduates (ECFMG), USA; certificate number 0-549-390-3, April 21st 1997

Brief Chronology of Employment:

- Investigator and Chief, Unit of Clinical and Translational Neuroscience, Laboratory of Behavioral Neuroscience, National Institute on Aging (NIA), National Institutes of Health (NIH): (August 2012-May 2019)

- Adjunct Professor of Neurology, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore: (since July 2018)
- Staff Clinician, Clinical Research Branch, National Institute on Aging (NIA), National Institutes of Health (NIH): (November 2007-August 2012)
- Alzheimer's Society Clinical Research Fellow, Kings College London (KCL), Institute of Psychiatry, London, United Kingdom (2004-2007)

Clinical Responsibilities (patient care and human clinical research protocols):

- Weekly outpatient clinic dedicated to care of patients referred to the Johns Hopkins Bayview Memory and Alzheimer's Treatment Center (MATC); 2009-current. This is an approved NIH official duty activity. Between June 2019 and June 2021, I evaluated 211 patients referred to the MATC (141 established; 70 new patients). Approximately 77% of the case mix of patients evaluated in my clinic are in-state and 23% out of state. The referrals represent the entire clinical spectrum of dementia diagnoses including sporadic and early onset Alzheimer's disease, Vascular dementia, Lewy Body dementia, Frontotemporal dementia, Parkinson's disease dementia, Normal pressure hydrocephalus as well as rare paraneoplastic and infectious etiologies of cognitive impairment. In addition, I also evaluate older adults with subjective memory complaints as well as cognitive impairment associated with mood disorders.
- Responsible clinician for non-autopsy research participants followed in the Baltimore Longitudinal Study of Aging (BLSA); 2012-current
- Principal Investigator; Resveratrol and Cardiovascular Health in the Elderly: REACHE Trial ([13-AG-0078](#)), NIA intramural research program; 2018-2021, [ClinicalTrials.gov Identifier: NCT01842399](#)
- Associate Investigator; Resveratrol and Cardiovascular Health in the Elderly: REACHE Trial ([13-AG-0078](#)), NIA intramural research program; 2021-current, [ClinicalTrials.gov Identifier: NCT01842399](#)
- Associate Investigator; Evaluation of [¹¹C]RO6924963, [¹¹C]RO6931643 and [¹⁸F]RO6958948 as tracers for tau imaging with positron emission tomography in healthy control subjects and subjects with Alzheimer's Disease, sponsor: F. Hoffmann La-Roche Ltd. [ClinicalTrials.gov Identifier: NCT02187627](#) (please see bibliography #66 for associated publication)
- Associate Investigator; Early Markers of Alzheimer's Disease: PET Tau Imaging in BLSA Participants, 2015-current
- Medically Responsible Investigator for Protocol ([06-M-0246](#)) PET scanning of brain dopaminergic signal transduction involving arachidonic acid in adults with attention deficit hyperactivity disorder (ADHD); NIMH, 2006-2012, [ClinicalTrials.gov Identifier: NCT00397748](#) (please see bibliography #24 for associated publication)

Service on Advisory committees to the U.S. Food and Drug Administration (FDA):

- Psychopharmacologic Drugs Advisory Committee (PDAC) evaluating supplemental new drug applications for NUPLAZID (pimavanserin) tablets, submitted by Acadia Pharmaceuticals Inc., for the proposed treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP); 2022

- Peripheral and Central Nervous System (PCNS) advisory committee evaluating Biologics License Application (BLA) 761178 for aducanumab solution for intravenous infusion, submitted by Biogen Inc., for the treatment of Alzheimer's disease; 2020
- Peripheral and Central Nervous System (PCNS) advisory committee evaluating new drug application (NDA) 202-008, florbetapir F-18 injection, sponsored by Avid Radiopharmaceuticals, Inc., proposed for use in positron emission tomography (PET) imaging of β -amyloid (beta-amyloid) aggregates in the brain to help rule out Alzheimer's disease; 2011
- External expert; Advisory Committee on Radioligands for Amyloid Imaging in Alzheimer's disease; Food and Drug Administration (FDA), October 2008

Societies and Professional Memberships:

- American Neurological Association (ANA); 2011: Elected member
- American Academy of Neurology; 1999-2004

Honors and Other Special Scientific Recognition:

- NIH Director's seminar series speaker; 2020
- TS Srinivasan Visiting Chair in Clinical Neuroscience, National Institute of Mental Health and Neurosciences (NIMHANS), India
- MV Arunachalam Endowment Oration award for contributions to clinical neurosciences, 2017
- Norman Geschwind Prize for outstanding achievements in Behavioral Neurology Research, American Academy of Neurology; 2016
- National Institute on Aging, Director's Merit Award for outstanding contribution to translational research in aging, public outreach and scientific leadership; 2014
- National Institute on Aging, Director's Merit Award for outstanding contribution to translational clinical research in aging; 2011
- National Institute on Aging (Office of the Scientific Director) On-the-Spot award for outstanding accomplishment in scientific research; 2010
- Emanoel Lee Medical Research Fellowship, St. Cross College, University of Oxford, United Kingdom; 2004-2007
- Felix Scholarship to the University of Oxford to read for the DPhil (Doctor of Philosophy) in Clinical Pharmacology; 1995-1999
- Rajiv Gandhi Summer Research Fellowship; Molecular Biophysics Unit, Indian Institute of Science; 1995

Grants/Funded Research:

- Studying blood chaperone proteins as tools for early diagnosis of Alzheimer's disease Posey Family Foundation \$18,000 PI: Thambisetty M; 2016-2018
- Studying blood chaperone proteins as tools for early diagnosis of Alzheimer's disease Posey Family Foundation \$15,000 PI: Thambisetty M; 2018-2020

- Studying blood chaperone proteins as tools for early diagnosis of Alzheimer's disease
Posey Family Foundation \$18,000 PI: Thambisetty M; 2020-2022
- Studying blood chaperone proteins as tools for early diagnosis of Alzheimer's disease
Posey Family Foundation \$18,000 PI: Thambisetty M; 2022-2024

Projects supported by NIA-IRP Special AD funds.

These are projects competitively reviewed by the NIA SD. They are subsequently presented to the Board of Scientific Counselors (BSC) and the NIA Planning group (PG). The funding stream is from congressional monies dedicated to support Alzheimer's disease research.

- September 2015: Predictive Blood and Cerebrospinal Fluid Metabolomic Markers in AD; \$358,440.00 Role: PI
- September 2017: Baltimore Longitudinal Study of Aging (BLSA) Database Consultancy services, \$ 149,919.00 Role: PI
- September 2017: Aptamer-based proteomic profiling of blood and brain tissue in Alzheimer's disease; \$ 783,000.00 Role: Co-PI with Dr. Luigi Ferrucci
- September 2019: Drug Repurposing for Effective Alzheimer's Medicines (**DREAM**) study; \$149,091.00 Role: PI
- September 2021: Preclinical Validation of Emerging Novel Treatments for Alzheimer's Disease (**PREVENT-AD**) study; \$2,250,000.00 Role: PI

Mentoring Activities (**including outreach increasing representation of women trainees): Pre-doctoral Mentees (**4 women; 3 men)

- Primary Mentor: Mr. Andrew Williamson; post-baccalaureate research fellow in the intramural research program, NIA, NIH; 2020-current
- Primary Mentor: Mr. Jackson Roberts; post-baccalaureate research fellow in the intramural research program, NIA, NIH; 2019-2020
- Primary Mentor: Ms. Uma Mahajan; post-baccalaureate research fellow in the intramural research program, NIA, NIH; 2018-2019; current Position: medical student at Case Western Reserve University
- Primary Mentor: Ms. Sahba Seddighi; post-baccalaureate research fellow in the intramural research program, NIA, NIH; 2016-2017; Gates Cambridge Scholar and MPhil student in Epidemiology, University of Cambridge, United Kingdom. Current Position: MSTP MD/PhD program, Johns Hopkins University School of Medicine, class of 2018
- Primary Mentor: Ms. Brittany Simpson; pre-doctoral research fellow in the intramural research program, NIA, NIH; 2014-2015 current Position: Resident in Pediatrics and Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati
- Co-Mentor: Mr. Bowen Tang, PhD Student, Karolinska Institute: Repurposing drugs for Alzheimer's disease: An epidemiological approach using causal inference methods; 2021- current
- Co-Mentor: Ms. Sarah Westwood, PhD Student, Institute of Psychiatry, King's College, London (Co-Supervisor) Thesis: Blood-based biomarkers of disease pathology in Alzheimer's disease; 2010-2013 Current Position: Postdoctoral researcher, Translational Neuroscience and Dementia Research Group, University of Oxford

Post-doctoral Mentees (**3 women; 2 men)

- Primary Mentor: Anjali Lathwal, PhD; post-doctoral research fellow in the intramural research program, NIA, NIH; 2021(terminated early due to family reasons). Current position: Research scientist, Tata Consultancy Services, New Delhi, India
- Primary Mentor: Vijay Varma, PhD; post-doctoral research fellow in the intramural research program, NIA, NIH; 2015-2019
- Primary Mentor: Alexandra Kueider, PhD; post-doctoral research fellow in the intramural research program, NIA, NIH; 2014-2017 Current Position: Research Associate, Department of Psychiatry, Duke University
- Primary Mentor: Yi-Fang Chuang, MD, PhD; post-doctoral research fellow in the intramural research program, NIA, NIH; 2013-2014 Current Position: Assistant Professor, Institute of Public Health, National Yang-Ming University, Taipei, Taiwan
- Primary Mentor: Donald Lyall, PhD; post-doctoral research fellow in the intramural research program, NIA, NIH; 2013-2014 Current Position: Lecturer in Public Health, University of Glasgow, United Kingdom

Plenary/Named Lectures and other notable invited talks:

- From mechanisms to medicines: realizing the DREAM of an Alzheimer's cure, Brain Health Imaging Institute Seminar, Cornell University, February 2022
- Aducanumab post-approval: Debates, dilemmas and decisions, University of Southern California ADRC, June 2021
- From mechanisms to medicines: realizing the DREAM of an Alzheimer's cure, Dementia Network Program, National University of Singapore, April 2021
- From mechanisms to medicines: realizing the DREAM of an Alzheimer's cure, Asian Society Against Dementia, October 2020
- From mechanisms to medicines: realizing the DREAM of an Alzheimer's cure, NIH Director's seminar series, September 2020
- From metabolomics to medicines: realizing the DREAM of an Alzheimer's cure, 9th Nantz National Alzheimer's Conference, Houston, February 2020
- From Chaperones to Epidemiology: seeking biomarkers and understanding mechanisms in Alzheimer's Disease; Protein and Glycan codes in Molecular Integrity and Stress Resilience, Agency for Medical Research and Development (AMED): Tokyo, September 2019
- The New Neurobiology of Dementia. XXIV World Congress of Neurology, Dubai, United Arab Emirates, October 2019
- Cerebrospinal fluid, Blood and Imaging Biomarkers of Alzheimer's Disease: Applications in Research and Clinical Practice. International Neurology Update, Kerala Association of Neurologists, Kochi, India, July 2019
- Understanding Alzheimer's Disease Pathogenesis: from Mechanisms to Medicines. Second International Conference, Promoting Healthy Brain Aging and Preventing Dementia: Research and Translation, Banff, Alberta, Canada, June 2018

- 15th MV Arunachalam Endowment Lecture, Chennai. Alzheimer's disease: from Mechanisms to Medicines; 2017
- Plenary speaker, 8th International workshop on HIV and Aging, New York, OMICS in the context of aging and Alzheimer's disease; 2017
- Brain and blood metabolite signatures of pathology and progression in Alzheimer's disease. Experimental Biology, Chicago, April 2017
- Plenary speaker, 10th International Congress of Asian Society Against Dementia (ASAD), Hangzhou, China. Risks, mechanisms and biomarkers: building an integrated approach to Alzheimer's disease; 2016
- Alpha2 Macroglobulin and Preclinical Alzheimer's Disease: A Marker of Neuronal Injury through the RCAN1 Pathway, Promoting Healthy Brain Aging and Preventing Dementia First International Conference, Banff, Alberta, Canada, June 2018
- Norman Geschwind Prize lecture in Behavioral Neurology, American Academy of Neurology, Vancouver. Obesity and obesity related behaviors: seeking a common neurobiology; 2016
- Plenary speaker, 3rd International Conference on Computational Biomedicine, University of Florida, Gainesville. Seeking biomarkers and understanding mechanisms: building an integrated approach to Alzheimer's disease; 2016
- Blood and Brain Metabolomics- Seeking Biomarkers and Understanding Mechanisms in Alzheimer's disease. Grand Rounds, Division of Geriatrics and Gerontology, University of Wisconsin School of Medicine, April 2016.
- Blood and Brain Metabolomics in Alzheimer's disease: Seeking Biomarkers and Understanding Mechanisms. Keio University symposium on Successful Brain Aging, Keio University, Tokyo, March 2016.
- The Acute Phase Response Protein Alpha2 Macroglobulin Predicts Incident Alzheimer's disease and Responds to Neuronal Injury through RCAN1. Campus Alberta Neuroscience International Conference on Promoting Healthy Brain Aging and Preventing Dementia: Research and Translation, May 2016
- Plenary speaker, 6th International meeting on HIV and aging. Washington, DC, October 2015. Insulin resistance, adiposity and risk for Alzheimer's disease; 2015
- Seeking Biomarkers and Understanding Mechanisms: Building an Integrated Approach to Risk in Alzheimer's Disease. 39th Annual Winter Meeting of The Toxicology Forum, Washington, DC, February 2015
- Brain imaging, risk variants and plasma proteomics: seeking biomarkers and understanding mechanisms in Alzheimer's disease. 8th Annual Meeting of the Asian Society Against Dementia, Colombo, Sri Lanka, November 2014
- Adiposity and Insulin Resistance in Alzheimer's Disease: When State Meets Trait. 8th Annual Meeting of the Asian Society Against Dementia, Colombo, Sri Lanka, November 2014
- The entorhinal cortex-hippocampal system is an early target of clusterin-related neurodegeneration in Alzheimer's disease. Co-chair; Featured Research Session on Clusterin: from Molecule to Man, International Conference on Alzheimer's Disease and Related Disorders, Copenhagen, 2014

- Insulin resistance and adiposity in Alzheimer's disease: when state meets trait. Johns Hopkins Department of Neurology, Grand Rounds, May 2014
- Insulin Resistance, Adiposity and Risk for Alzheimer's disease. The Johns Hopkins ADRC Annual Conference on Aging and Dementia, June 2014
- APOE and partners in the post GWAS era: discovering biomarkers and understanding mechanisms in Alzheimer's Disease. Fourth annual symposium on ApoE, ApoE Receptors and Neurodegeneration. Georgetown University, June 2013
- Brain imaging, risk variants and plasma proteomics: seeking biomarkers and understanding mechanisms in Alzheimer's disease. Douglas Mental Health University Institute – Research Centre. McGill University, Montreal, March 2013
- Alzheimer's disease: seeking biomarkers and understanding mechanisms. NIH Clinical Center Grand Rounds, Bethesda 2013
- Is it memory loss or Alzheimer's disease? Learn the facts. Medicine for the Public lecture series. Suburban Hospital, Washington, DC 2012
- Brain imaging, risk variants and plasma proteomics: seeking biomarkers and understanding mechanisms in Alzheimer's disease. New York University Center for Brain Health, New York, December 2012
- Keynote speaker, Advisory Committee on Radioligands for Amyloid Imaging in Alzheimer's disease; Food and Drug Administration (FDA), Clinical features, Diagnosis and Management of Alzheimer's disease; 2011
- President's Plenary session; International College of Geriatric Psych neuropharmacology, University of California, Irvine, Neuroimaging and Genetic Findings in Alzheimer's Disease from the Baltimore Longitudinal Study of Aging; 2011
- Neuroimaging guided proteomic discovery of blood biomarkers for Alzheimer's disease. Institute of Psychiatry, Kings College, London, May 2011
- Plenary speaker, 6th Annual Update on the Treatment of Alzheimer's and Related Disorders. The Johns Hopkins Alzheimer's Disease Research Center, The Role of Emerging Biotechnologies in Dementia Care; 2010
- Plenary speaker and faculty; The Role of Emerging Biotechnologies in Dementia Care. 16th Annual CME Update on the Treatment of Alzheimer's and Related Disorders. The Johns Hopkins Alzheimer's Disease Research Center; 2010
- Plenary speaker; International College of Geriatric Psych neuropharmacology, Johns Hopkins University School of Medicine Alzheimer's disease: New Frontiers in Biomarkers and Therapeutics; 2009
- Novel Approaches to Peripheral Biomarker Discovery in Alzheimer's disease. Interdisciplinary Program in Neuroscience, Georgetown University, November 2009
- Clinical features, Diagnosis and Management of Alzheimer's disease. External expert speaker; Advisory Committee on Radioligands for Amyloid Imaging in Alzheimer's disease; Food and Drug Administration (FDA), October 2008
- Proteome and Neuroimaging-based Plasma Biomarkers for Alzheimer's disease: Insights into Vascular Mechanisms of Pathogenesis. Johns Hopkins Alzheimer's Disease Research

Center, Annual Dementia Retreat, Baltimore, May 2008

- Proteomic and Neuroimaging Approaches to Peripheral Biomarkers in Alzheimer's disease. American College of Neuropsychopharmacology, Florida, 2007
- Novel Approaches to Peripheral Biomarkers in Alzheimer's Disease. National Institute on Aging (NIA), National Institutes of Health (NIH, Baltimore, August 2006
- The Proteomics of Alzheimer's Disease. National Neuroscience Institute, Singapore General Hospital, 8th March 2006
- A Novel Approach to Peripheral Biomarkers in Alzheimer's Disease. Department of Biochemistry, National University of Singapore, March 2006
- Proteomic Approaches to Early Diagnosis of Alzheimer's Disease. Neurocal-2005-Neuroscience Society of Calicut Medical College, India, May 2005
- Genetic Testing and Counselling in Dementia. Luigi Amaducci Teaching Course in Dementia-European Federation of Neurological Societies (EFNS), Athens, Greece, September 2005
- Lecturer, MSc course in Neuroscience, Kings College, London, U.K.; 2004-2007

Other Professional Activities:

- Vice Chair, Board of Trustees, McKnight Brain Research Foundation, 2019-current
- NIA IRP Search Committee, tenure-track investigators and staff scientist recruitment, 2020
- NIDA IRP Search Committee, tenure-track investigator recruitment, 2020
- Reviewer, NIA-NIEHS Joint fellowship program; 2018
- NIH Study section on 'Interdisciplinary research to understand the complex biology of resilience to Alzheimer's disease risk (RO1); 2017
- NIA IRP Search Committee, Staff Clinician, Clinical Research Core; 2017
- NIA IRP Search Committee, Staff Scientist Facility Head, LGG Computational Biology Core; 2017
- National Cancer Institute, Neuro-oncology Branch, Search Committee, Tenure-Eligible Principal Investigator; 2016
- NIA IRP Laboratory specialist promotion committee; 2014-2016
- NIH Earl Stadtman Investigator search committee (Systems Biology); 2013-current
- NIA IRP Search Committee, Staff Scientist, Translational Gerontology Branch; 2013
- PhD Thesis Examiner; University of New South Wales, Australia. The roles of sirtuins and polyphenols in brain ageing and neurodegeneration, Tharushi Jayasena, 2016
- Member's chair, American Neurological Association (ANA); Interactive Lunch Workshop Taskforce. Develop and organize workshops on topics of their expertise at the annual ANA meeting; 2012-2015
- OMICS in the context of aging and Alzheimer's disease, 8th International workshop on HIV and Aging, New York, NY; October 2017
- Co-chair; Featured Research Session on Clusterin: from Molecule to Man, International Conference on Alzheimer's Disease and Related Disorders, Copenhagen, Denmark; July 2014

Adhoc Reviewer:

JAMA NEJM

Nature Aging Neurobiology of Aging Biological Psychiatry

Journal of Alzheimer's Disease

PLOS ONE

PLOS Medicine

Alzheimer's and

Dementia Neurology

Neuroimage

CNS Drugs

Other professional experience:

- Teaching faculty to residents in Medicine/Geriatric Medicine rotating through the Memory and Alzheimer's Treatment Center, Johns Hopkins Bayview Medical Center, Johns Hopkins University School of Medicine; 2009-current
- Faculty: Aging and Age-related Cognitive Disorders training course, Johns Hopkins University School of Medicine; 2011-current
- Faculty: Circuits and Brain Disorders' co-sponsored by the Department of Neuroscience and the Johns Hopkins ADRC; 2020-current
- Lecturer, MSc course in Neuroscience, Kings College, London, U.K.; 2004-2007
- Faculty, training program in cognitive screening for dementia in India; sponsored by the British Academy and in collaboration with the Oxford Project to Investigate Memory and Aging (OPTIMA); 2006
- Faculty, Luigi Amaducci Teaching Course in Dementia-European Federation of Neurological Societies (EFNS), Athens, Greece; 2005

Conference organization:

- Co-convenor, NIA workshop; 'Towards interventions for healthy aging: closing the translational gap'; October 2021
- Co-convenor, NIA workshop; 'Biology underlying moving and thinking'; December 2021
- Organizing committee, International workshop on HIV and Aging, 2017-current

Service on editorial boards:

Associate Editor; Journal of Alzheimer's Disease; 2011-2012

Associate Editor; Journal of Alzheimer's Disease; 2018-2022

BIBLIOGRAPHY*Madhav TR and Madhav Thambisetty denote the same author*

1. **Madhav TR**, Vatsala S, Ramakrishna T Ramesh J, Easwaran KR. Preservation of native conformation during aluminium-induced aggregation of tau protein. NeuroReport. 7(5): 1072-6, (1996) PMID: pending
2. Ramakrishna T, Vatsala S, **Madhav TR**, Sreekumaran E, Ramesh, J, Easwaran, KRK. Conformational Change in β - amyloid Peptide (1-40) with Aluminium: Reversal by Borate. Alzheimer's Research. 3: 223-226, (1997) PMID: pending
3. Ramakrishna T, Vatsala S, Shobi V, Sreekumaran E, **Madhav TR**, Ramesh, J, Easwaran, KRK. Betaine reverses toxic effects of aluminium: Implications in Alzheimer's disease (AD) and AD-like pathology. Current Science. 75 (11): 1153-1156, (1998) PMID: pending
4. Ramesh J, **Madhav TR**, Vatsala S Ramakrishna T, Easwaran KRK, Guillard O, Deloncle R. Interaction of A beta peptide (1-40) with amino acid aluminium complexes: relevance to Alzheimer's disease. Alzheimer's Reports. 2 (1): 31-35, (1999) PMID: pending
5. Zetterström TS, Pei Q, **Madhav TR**, Coppell AL, Lewis L, Grahame-Smith DG. Manipulations of brain 5-HT levels affect gene expression for BDNF in rat brain. Neuropharmacology. 38 (7): 1063-1073, (1999) PMID: pending
6. **Madhav TR**, Pei Q, Grahame-Smith DG, Zetterström TS. Repeated electroconvulsive shock promotes the sprouting of serotonergic axons in the lesioned rat hippocampus. Neuroscience. 97 (4): 677-683, (2000) PMID: pending
7. **Madhav TR**, Pei Q, Zetterström TS. Serotonergic cells of the rat raphe nuclei express mRNA of tyrosine kinase B (trkB), the high-affinity receptor for brain derived neurotrophic factor (BDNF). Brain Research. Molecular Brain Research. 93 (1): 56-63, (2001) PMID: pending
8. **Thambisetty M**, Scherzer CR, Yu Z Lennon VA, Newman NJ. Paraneoplastic optic neuropathy and cerebellar ataxia with small cell carcinoma of the lung. Journal of Neuro-Ophthalmology. 21(3): 164-167, (2001) PMID:11725180
9. **Thambisetty M**, Newman NJ, Glass JD, Frankel MR. A Practical approach to the diagnosis and management of MELAS: case report and review. The Neurologist. 8(5): 302-312, (2002) PMID:12803677
10. **Thambisetty M**, Biousse V, Newman NJ. Hypertensive brainstem encephalopathy: clinical and radiographic features. Journal of the Neurological Sciences. 208 (1-2): 93-99, (2003) PMID: pending
11. Sreekumaran E, Ramakrishna T, **Madhav TR**, Anandh D, Prabhu BM, Sulekha S,

Bindu PN, Raju TR. Loss of dendritic connectivity in CA1, CA2 and CA3 neurons in hippocampus in rat under aluminum toxicity: antidotal effect of pyridoxine. Brain Research Bulletin. 59(6): 421-427, (2003) PMID: pending

12. Hye A, Lynham S, **Thambisetty M**, Causevic M, Campbell J, Byers HL, Hooper C, Rijdsdijk F, Tabrizi SJ, Banner S, Shaw CE, Foy C, Poppe M, Archer N, Hamilton G, Powell J, Brown RG, Sham P, Ward M, Lovestone S. Proteome-based plasma biomarkers for Alzheimer's disease. Brain. 68:229-232, (2006) PMID: pending
13. **Thambisetty M**, Biousse V, Lavine PJ, Newman NJ, Biousse V. Fulminant idiopathic intracranial hypertension. Neurology. 68:229-232, (2007) PMID:17224579
14. David B. Rye, Andrew Hicks, Hjorvar Petursson, Ingason A, Thorgeirsson TE, Palsson S, Sigmundsson T, Sigurdsson AP, Eiriksdottir I, Soebach E, Bliwise D, Beck JM, Rosen A, Waddy S, Trotti LM, Iranzo A, **Thambisetty M**, Hardarson GA, Kristjansson K, Gudmundsson LJ, Thorsteinsdottir U, Kong A, Gulcher JR, Gudbjartsson D, Stefansson K. A genetic risk factor for periodic limb movements in sleep. New England Journal of Medicine. 357(7): 639-647, (2007) PMID:17634447
15. De Jager CA, **Thambisetty M**, Praveen KV, Sheeba PD, Ajini KN, Sajeev A, Smitha KK, Rahmathulla LP, Ramakrishna T, David SA. Utility of the Malayalam translation of the 7-minute screen for Alzheimer's disease risk in an Indian community. Neurology India. 56(2):161-6, (2008) PMID: pending
16. **Thambisetty M**, A Hye, C Foy, E Daly, Glover A, Cooper A, Simmons A, Murphy D, Lovestone S. Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease. Journal of Neurology. 255(11):1712-20, (2008) PMID: pending
17. Greenberg N, Grassano A, **Thambisetty M**, Lovestone S, Legido-Quigley C. A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease. Electrophoresis. 30(7): 1235-1239, (2009) PMID: pending
18. **Thambisetty M**, Beason-Held L, An, Y, Kraut MA, Resnick SM. APOE ϵ 4 genotype and longitudinal changes in regional cerebral blood flow during normal aging. Archives of Neurology. 67(1): 93-98, (2010) PMID: PMC2856443
19. **Thambisetty M**, Wan J, Carass A, An Y, Prince JL, Resnick SM. Longitudinal changes in cortical thickness associated with normal aging. Neuroimage. 52(4): 1215-1223, (2010) PMID: PMC2910226
20. **Thambisetty M**, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y,

Wahlund LO, Westman E, Kinsey A, Güntert A, Proitsi P, Powell J, Causevic M, Killick R, Lunnon K, Lynham S, Broadstock M, Choudhry F, Howlett DR, Williams RJ, Sharp SI, Mitchelmore C, Tunnard C, Leung R, Foy C, O'Brien D, Breen G, Furney SJ, Ward M, Kloszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Hodges A, Murphy DG, Parkins S, Richardson JC, Resnick SM, Ferrucci L, Wong DF, Zhou Y, Muehlboeck S, Evans A, Francis PT, Spenger C, Lovestone S. Association of plasma clusterin concentration with severity, pathology and progression in Alzheimer's disease. Archives of General Psychiatry. 67(7): 739-748, (2010) PMID: PMC3111021

21. **Thambisetty M**, Tripaldi R, Riddoch-Contreras J, Hye A, An Y, Campbell J, Sojkova J, Kinsey A, Lynham S, Zhou Y, Ferrucci L, Wong DF, Lovestone S, Resnick SM. Proteome-based plasma markers of brain amyloid beta deposition in non-demented older individuals. Journal of Alzheimer's Disease. 22(4):1099-109, (2010) PMID: PMC3125970
22. **Thambisetty M**, Simmons A, Hye A, Campbell J, Westman E, Zhang Y, Wahlund LO, Kinsey A, Causevic M, Killick R, Kloszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Spenger C, Lovestone S. Plasma biomarkers of brain atrophy in Alzheimer's disease. PLOS ONE. 6(12):e28527, (2011) PMID: PMC3244409
23. **Thambisetty M**, An Y, Kinsey A, Koka D, Saleem M, Güntert A, Kraut M, Ferrucci L, Davatzikos C, Lovestone S, Resnick SM. Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment. Neuroimage. 59(1):212-7, (2012) PMID: PMC3425349
24. **Thambisetty M**, Gallardo KA, Liow JS, Beason-Held LL, Umhau JC, Bhattacharjee AK, Der M, Herscovitch P, Rapoport JL, Rapoport SI. The utility of ¹¹C-arachidonate PET to study in vivo dopaminergic neurotransmission in humans. Journal of Cerebral Blood Flow and Metabolism. 32(4):676-84, (2012) PMID: PMC3318145
25. Beason-Held L, **Thambisetty M**, Deib G, Sojkova J, Landman BA, Zonderman AB, Ferrucci L, Kraut MA, Resnick SM. Baseline cardiovascular risk predicts subsequent changes in resting brain function. Stroke. 43(6):1542-1547, (2012) PMID: PMC3361601
26. Soares H, Potter W, Pickering E, Kuhn M, Immermann FW, Shera DM, Ferm M, Dean RA, Simon AJ, Swenson F, Siuciak JA, Kaplow J, **Thambisetty M**, Zagouras P, Koroshetz WJ, Wan HI, Trojanowski JQ, Shaw LM. Plasma biomarkers associated with ApoE genotype and Alzheimer's disease. Archives of Neurology. 69(10):1310-7, (2012) PMID: PMC3683865
27. Kiddle S, **Thambisetty M**, Simmons A, Riddoch-Contreras J, Hye A, Westman E, Pike I, Ward M, Johnston C, Lupton MK, Lunnon K, Soininen H, Kloszewska I, Tsolaki M, Vellas B, Mecocci P, Lovestone S, Newhouse S, Dobson R. Plasma based markers of [11C] PiB-PET brain amyloid burden. PLOS ONE. 7(9):e44260, (2012) PMID:

PMC3454385

28. Cuddy M, Papps BJ, **Thambisetty M**, Leigh PN, Goldstein LH. Processing and memory for emotional and neutral material in amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis*. 13(6):592-8, (2012) PMID: [PMC5898366](#)
29. **Thambisetty M**, An Y, Nalls M, Sojkova J, Swaminathan S, Zhou Y, Singleton AB, Wong DF, Ferrucci L, Saykin AJ, Resnick SM. The effect of complement CR1 on brain amyloid burden during aging and its modification by APOE genotype. *Biological Psychiatry*. 73(5):422-8, (2013) PMID: [PMC3535537](#)
30. **Thambisetty M**, Beason-Held LL, An Y, Kraut M, Nalls M, Hernandez DG, Singleton AB, Zonderman AB, Ferrucci L, Lovestone S, Resnick SM. Alzheimer risk variant clusterin (*CLU*) and brain function in aging. *Biological Psychiatry*. 73(5):399-405, (2013) PMID: [PMC3488132](#)
31. **Thambisetty M**, Jeffrey Metter E, Yang A, Dolan H, Marano C, Zonderman AB, Troncoso JC, Zhou Y, Wong DF, Ferrucci L, Egan J, Resnick SM, O'Brien RJ. Glucose intolerance, insulin resistance and Alzheimer's disease pathology in the Baltimore Longitudinal Study of Aging. *JAMA Neurology*. 70(9): 1167-72, (2013) PMID: [PMC3934653](#)
32. **Thambisetty M**, Beason-Held LL, An Y, Kraut M, Metter J, Egan J, Ferrucci L, O'Brien R, Resnick SM. Impaired Glucose Tolerance in Midlife and Longitudinal Changes in Brain Function During Aging. *Neurobiology of Aging*. 34(10):2271-6, (2013) PMID: [PMC4577027](#)
33. **Thambisetty M**, An Y, Tanaka T. Alzheimer disease risk genes and the age-at-onset phenotype. *Neurobiology of Aging*. 34(11) 2696.e1-5 (2013) PMID: [PMC4038407](#)
34. Whiley L, Sen A, Heaton J Proitsi P, García-Gómez D, Leung R, Smith N, **Thambisetty M**, Kloszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Lovestone S, Legido-Quigley C. Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease. *Neurobiology of Aging*. 35(2):271-8 (2014) PMID: [PMC5866043](#)
35. Hales CM, Rees H, Seyfried NT Dammer EB, Duong DM, Gearing M, Montine TJ, Troncoso JC, **Thambisetty M**, Levey AI, Lah JJ, Wingo TS. Abnormal gephyrin immunoreactivity associated with Alzheimer disease pathologic changes. *J Neuropathol Exp Neurol*. 72(11):1009-15 (2013) PMID: [PMC4037931](#)
36. Herskowitz JH, Feng Y, Mattheyses AL, Hales CM, Higginbotham LA, Duong DM, Montine TJ, Troncoso JC, **Thambisetty M**, Seyfried NT, Levey AI, Lah JJ. Pharmacologic

inhibition of ROCK2 suppresses amyloid- β production in an Alzheimer disease mouse model. J Neuroscience. 33(49):19086-98 (2013) PMID: PMC3850036

37. Hales CM, Seyfried NT, Dammer EB, Duong D, Yi H, Gearing M, Troncoso JC, Mufson EJ, **Thambisetty M**, Levey AI, Lah JJ. U1 small nuclear ribonucleoproteins (snRNPs) aggregate in Alzheimer's disease due to autosomal dominant genetic mutations and trisomy 21. Mol Neurodegeneration. 9(1):15 (2014) PMID: PMC4022210
38. Diner I, Chadwick HM, Bishof I, Rabenold L, Duong DM, Yi H, Laur O, Gearing M, Troncoso J, **Thambisetty M**, Lah JJ, Levey AI and Seyfried NY. Aggregation properties of the small nuclear ribonucleoprotein U1-70K in Alzheimer Disease. Journal of Biological Chemistry. 289(51):35296-313 (2014) PMID: PMC4271217
39. Chuang Y-F, Tanaka T, Beason-Held L, An Y, Terracciano A, Sutin AR, Kraut M, Singleton AB, Resnick SM, **Thambisetty M**. *FTO* genotype and aging: pleiotropic longitudinal effects on adiposity, brain function, impulsivity and diet. Molecular Psychiatry. 20(1):133-139 (2015) PMID: PMC4246032
40. Ebshiana AA, Snowden SG, **Thambisetty M**, Parsons R, Hye A, Legido-Quigley C. Metabolomic method: UPLC-q-ToF polar and non-polar metabolites in the healthy rat cerebellum using an in-vial dual extraction. PLOS ONE. 10(4):e0122883 (2015) PMID: PMC4390242
41. Resnick SM, Bilgel M, Moghekar A, An Y, Cai Q, Wang MC, **Thambisetty M**, Prince JL, Zhou Y, Soldan A, Wong DF, O'Brien RJ, Ferrucci L, Albert MS. Changes in A β biomarkers and associations with APOE genotype in 2 longitudinal cohorts. Neurobiology of Aging. 36(8):2333-9 (2015) PMID:26004017
42. Khan W, Aguilar C, Kiddle SJ, Doyle O, **Thambisetty M**, Muehlboeck S, Sattlecker M, Newhouse S, Lovestone S, Dobson R, Giampietro V, Westman E, Simmons A; Alzheimer's Disease Neuroimaging Initiative. A Subset of Cerebrospinal Fluid Proteins from a Multi-Analyte Panel Associated with Brain Atrophy, Disease Classification and Prediction in Alzheimer's Disease. PLOS ONE. 10(8):e0134368 (2015) PMID: PMC4540455
43. Du W, Cheung H, Goldberg I, **Thambisetty M**, Becker K, Johnson CA. A Longitudinal Support Vector Regression for Prediction of ALS Score. IEEE Int Conf Bioinform Biomed Workshops. 2015:1586-1590(2015). PMID: PMC4814169
44. Gupta VB, Doecke JD, Hone E, Pedrini S, Laws SM, **Thambisetty M**, Bush AI, Rowe CC, Villemagne VL, Ames D, Masters CL, Macaulay SL, Rembach A, Rainey-Smith SR, Martins RN; AIBL Research Group. Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging. Alzheimer's and Dementia. 3:18-26 (2015) PMID: PMC4879652

45. Kueider AM, Tanaka T, An Y, Kitner-Triolo MH, Palchamy E, Ferrucci L, **Thambisetty M**. State and trait-dependent associations of vitamin-D with brain function during aging. Neurobiology of Aging. 39:38-45 (2016) PMID: PMC4773992
46. Chuang YF, Yang A, Bilgel M, Wong DF, Troncoso JC, O'Brien RJ, Breitner JC, Ferrucci L, Resnick SM, **Thambisetty M**. Midlife adiposity predicts earlier onset of Alzheimer's dementia, neuropathology and presymptomatic cerebral amyloid accumulation. Molecular Psychiatry. 21(7):910-5 (2016) PMID: PMC5811225
47. Simpson BN, Min K, Lirette S, Windham GB, Ferrucci L, Griswold ME, Legido-Quigley C, **Thambisetty M**. Blood metabolite markers associated of cognitive performance and brain function in aging. Journal of Cerebral Blood Flow and Metabolism. 36(7):1212-23 (2016) PMID: PMC4929698
48. Casanova R, Varma S, Simpson B, Min K, An Y, Saldana S, Moscato P, Griswold M, Sonntag D, Wahrheit J, Legido-Quigley C, **Thambisetty M**. Blood metabolite markers of preclinical Alzheimer's disease in two longitudinally followed cohorts of older individuals Alzheimer's and Dementia. 12(7):815-22 (2016) PMID: PMC4947451
49. Westwood S, Leoni E, Hye A, Lynham S, Khondoker M, Kiddle SJ, Ashton NJ, Baird AL, Sainz Fuertes R, Bazenet C, Ward M, **Thambisetty M**, Lovestone S. Blood-based biomarker candidates of cerebral amyloid using PiB PET in non-demented elderly. Journal of Alzheimer's Disease. 52(2):561-72 (2016) PMID: PMC5898378
50. Wennberg AMV, Spira AP, Pettigrew C, Soldan A, Zipunnikov V, Rebok GW, Roses AD, Lutz MW, Miller MM, **Thambisetty M**, Albert MS. Blood glucose levels and cortical thinning in cognitively normal, middle-aged adults. Journal of the Neurological Sciences. 365:89-95(2016) PMID: PMC4876973
51. Henderson BW, Gentry EG, Rush T, Troncoso JC, **Thambisetty M**, Montine TJ, Herskowitz JH. Rho-associated protein kinase 1 (ROCK1) is increased in Alzheimer's disease and ROCK1 depletion reduces amyloid- β levels in brain. Journal of Neurochemistry. 138(4):525-31 (2016) PMID: PMC4980252
52. Kim M, Nevado-Holgado A, Whiley L, Snowden SG, Soininen H, Kloszewska I, Mecocci P, Tsolaki M, Vellas B, **Thambisetty M**, Dobson R, Powell J, Lupton MK, Simmons A, Velayudhan L, Lovestone S, Proitsi P, Legido-Quigley C. Association between plasma ceramides and phosphatidylcholines and hippocampal brain volume in Late Onset Alzheimer's Disease. Journal of Alzheimer's Disease. 60(3):809-817 (2016) PMID: PMC5676755

53. Hales CM, Dammer EB, Deng Q, Duong DM, Gearing M, Troncoso JC, **Thambisetty M**, Lah JJ, Shulman JM, Levey AI, Seyfried NT. Changes in the detergent-insoluble brain proteome linked to amyloid and tau in Alzheimer's Disease progression. Proteomics. 16(23):3042-3053 (2016) PMID: PMC5462625
54. Goodman RA, Lochner KA, **Thambisetty M**, Wingo TS, Posner SF, Ling SM. Prevalence of dementia subtypes in U.S. Medicare fee-for-service beneficiaries, 2011-2013. Alzheimer's and Dementia. 13(1):28-37 (2016) PMID: PMC5104686
55. Varma VR, Varma V, An Y, Hohman TJ, Seddighi S, Casanova R, Beri A, Dammer EB, Seyfried NT, Pletnikova O, Moghekar A, Wilson MR, Lah JJ, O'Brien RJ, Levey AI, Troncoso JC, Albert M, **Thambisetty M**. Alpha-2 macroglobulin in Alzheimer's disease: a marker of neuronal injury through the RCAN1 pathway. Molecular Psychiatry. 22(1):13-23 (2017) PMID: PMC5726508
56. Seyfried NT, Dammer EB, Swarup V, Nandakumar D, Duong DM, Yin L, Deng O, Nguyen T, Hales CM, Wingo T, Glass J, Gearing M, **Thambisetty M**, Troncoso JC, Geschwind DH, Lah JJ, Levey AI. A multi-network approach identifies protein-specific co-expression in asymptomatic and symptomatic Alzheimer's disease. Cell Systems. 4(1):60-72.e4 (2016) PMID: PMC5269514
57. Snowden SG, Ebshiana AA, Hye A, An Y, Pletnikova O, O'Brien RJ, Troncoso J, Legido-Quigley C, **Thambisetty M**. Association between fatty acid metabolism in the brain and Alzheimer's disease neuropathology and cognitive performance: a non-targeted metabolomics study. PLOS Medicine. 14(3):e1002266 (2017) PMID: PMC5360226
58. Toledo JB, Arnold M, Kastenmüller G, Chang R, Baillie RA, Han X, **Thambisetty M**, Tenenbaum JD, Suhre K, Thompson JW, John-Williams LS, MahmoudianDehkordi S, Rotroff DM, Jack JR, Motsinger-Reif A, Risacher SL, Blach C, Lucas JE, Massaro T, Louie G, Zhu H, Dallmann G, Klavins K, Koal T, Kim S, Nho K, Shen L, Casanova R, Varma S, Legido-Quigley C, Moseley MA, Zhu K, Henrion MY, van der Lee SJ, Harms AC, Demirkan A, Hankemeier T, van Duijn CM, Trojanowski JQ, Shaw LM, Saykin AJ, Weiner MW, Doraiswamy PM, Kaddurah-Daouk R; Alzheimer's Disease Neuroimaging Initiative and the Alzheimer Disease Metabolomics Consortium. Metabolic network failures in Alzheimer's disease-A biochemical road map. Alzheimer's and Dementia. 13(9):965-984 (2017) PMID: PMC5866045
59. **Thambisetty M** Understanding mechanisms and seeking cures for Alzheimer's disease: Why we must be "extraordinarily diverse". American Journal of Physiology Cell Physiology. 313(4):C353-C361 (2017) PMID: PMC5668578
60. Chuang YF, Yang A, Elango P, Gonzalez CE, **Thambisetty M**. Midlife anticholinergic drug use, risk of Alzheimer's disease and brain atrophy in community-dwelling older adults.

Alzheimer's and Dementia Translational Research and Clinical Interventions. 3(3):471-479 (2017) PMID: [PMC5651434](#)

61. Kueider AM, An Y, Tanaka T, Kitner-Triolo MH, Studenski S, Ferrucci L, **Thambisetty M**. Sex-dependent Associations of serum uric acid with brain function during aging. Journal of Alzheimer's Disease. 60(2):699-706 (2017) PMID: [PMC6112110](#)
62. Seddighi S, Varma VR, An Y, Varma S, Beason-Held LL, Tanaka T, Kitner-Triolo MH, Kraut MA, Davatzikos C, **Thambisetty M**. *SPARCLI* Accelerates Symptom Onset in Alzheimer's Disease and Influences Brain Structure and Function During Aging. Journal of Alzheimer's Disease. 61(1):401-414 (2018) PMID: [PMC5934753](#)
63. An Y, Varma VR, Varma S, Casanova R, Dammer E, Pletnikova O, Chia CW, Egan JM, Ferrucci L, Troncoso J, Levey AI, Lah J, Seyfried NT, Legido-Quigley C, O'Brien R, **Thambisetty M**. Evidence for Brain Glucose Dysregulation in Alzheimer's Disease. Alzheimer's and Dementia. 14(3):318-329 (2018) PMID: [PMC5866736](#)
64. Varma VR, Oommen AM, Varma S, Casanova F, An Y, Andrews RM, O'Brien R, Pletnikova O, Troncoso JC, Toledo J, Baillie R, Arnold M, Kastenmueller G, Nho K, Doraiswamy M, Saykin AJ, Kaddurah-Daouk R, Legido-Quigley C, **Thambisetty M**. Brain and Blood Metabolite Signatures of Pathology and Progression in Alzheimer's Disease. PLOS Medicine. 15(1): e1002482 (2018) PMID: [PMC5784884](#)
65. Hohman TJ, Dumitrescu L, Barnes LL, **Thambisetty M**, Beecham G, Kunkle B, Gifford K, Bush WS, Chibnik LB, Mukherjee S, De Jager PL, Kukull W, Crane PK, Resnick SM, Keene CD, Montine TJ, Schellenberg GD, Haines JL, Zetterberg H, Blennow K, Larson EB, Johnson SC, Albert M, Bennett DA, Schneider JA, Jefferson AL for the Alzheimer's Disease Genetics Consortium and the Alzheimer's Disease Neuroimaging Initiative. Sex-specific effects of Apolipoprotein E on cerebrospinal fluid levels of tau. JAMA Neurology. 75(8):989-998 (2018) PMID: [PMC6142927](#)
66. Wong DF, Comley R, Kuwabara H, Rosenberg PB, Resnick SM, Ostrowitzki S, Vozzi C, Boess F, Oh E, Lyketsos CG, Honer M, Gobbi L, Klein G, George N, Gapasin L, Kitzmiller K, Roberts J, Sevigny J, Nandi A, Brasic JR, Mishra C, **Thambisetty M**, Moghekar A, Mathur A, Albert M, Dannals RF, Borroni E. First in-human PET study of 3 novel tau radiopharmaceuticals: [¹¹C]RO6924963, [¹¹C]RO6931643, and [¹⁸F]RO6958948. Journal of Nuclear Medicine. 11(3):427-435 (2018) PMID: [PMC7035908](#)
67. Shi L, Baird AL, Westwood S, Hye A, Dobson R, **Thambisetty M**, Lovestone S. A Decade of Blood Biomarkers for Alzheimer's Disease Research: An Evolving Field, Improving Study Designs, and the Challenge of Replication. Journal of Alzheimer's Disease. 62(3):1181-1198. (2018) PMID: [PMC5870012](#)

68. Deming Y, Dumitrescu L, Barnes LL, **Thambisetty M**, Kunkle B, Gifford KA, Bush WS, Chibnik LB, Mukherjee S, De Jager PL, Kukull W, Huentelman M, Crane PK, Resnick SM, Keene CD, Montine TJ, Schellenberg GD, Haines JL, Zetterberg H, Blennow K, Larson EB, Johnson SC, Albert M, Moghekar A, del Aguila JL, Fernandez MV, Budde J, Hassenstab J, Fagan AM, Riemenschneider M, Petersen RC, Minthon L, Chao MJ, Van Deerlin VM, Lee VM, Shaw LM, Trojanowski JQ, Peskind ER, Li G, Davis LK, Sealock JM, Cox NJ, for the Alzheimer's Disease Neuroimaging Initiative (ADNI), for the Alzheimer's Disease Genetics Consortium (ADGC), Goate AM, Bennett DA, Schneider JA, Jefferson AL, Cruchaga C., Hohman TJ. Sex-specific genetic predictors of Alzheimer's disease biomarkers. *Acta Neuropathologica* 136(6):857-872 (2018) PMID: [PMC6280657](#)
69. Bell WR, An Y, Kageyama Y, Rudow GL, Pletnikova O, **Thambisetty M**, O'Brien R, Moghekar AR, Albert MS, Rabins PV, Resnick SM, Troncoso JC. Neuropathologic, genetic, and longitudinal cognitive profiles in primary age-related tauopathy (PART) and Alzheimer disease (AD). *Alzheimer's and Dementia* 15(1):8-16 (2018) PMID: [PMC6542566](#)
70. Erik C.B. Johnson, Eric B. Dammer, Duc M. Duong, Luming Yin, **Thambisetty M**, Juan C. Troncoso, James J. Lah, Allan I. Levey, Nicholas T. Seyfried. Deep proteomic network analysis of Alzheimer's disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease. *Molecular Neurodegeneration* 13:52 (2018) PMID: [PMC6172707](#)
71. Bowman K, **Thambisetty M**, Kuchel G, Ferrucci L, Melzer D. Obesity and longer term risks of dementia in 65 to 74 year olds. *Age and Ageing* 48(3):367-373 (2019) PMID: [PMC6512743](#)
72. Wingo AP, Dammer EB, Breen MS, Logsdon BA, Duong DM, Yang J, Troncoso JC, **Thambisetty M**, Beach TG, Reiman E, Lah JJ, Seyfried NT, Levey AI, Wingo TS. Large-scale proteomic analysis of human brain identifies proteins associated with cognitive trajectory in advanced age. *Nature Communications* 10(1):1619 (2019) PMID: [PMC6453881](#)
73. Dumitrescu L, Barnes LL, **Thambisetty M**, Beecham G, Kunkle B, Bush WS, Gifford KA, Chibnik LB, Mukherjee S, De Jager PL, Kukull W, Crane PK, Resnick SM, Keene CD, Montine TJ, Schellenberg GD, Deming Y, Chao MJ, Huentelman M, Martin ER, Hamilton-Nelson K, Shaw LM, Trojanowski JQ, Peskind ER, Cruchaga C, Pericak-Vance MA, Goate AM, Cox NJ, Haines JL, Zetterberg H, Blennow K, Larson EB, Johnson SC, Albert M, for the Alzheimer's Disease Genetics Consortium and the Alzheimer Disease Neuroimaging Initiative, Bennett DA, Schneider JA, Jefferson AL, Hohman TJ. Sex differences in the genetic predictors of Alzheimer's pathology. *Brain* 142(9):2581-2589 (2019) PMID: [PMC6736148](#)

74. Snowden SG, Ebshiana AA, Hye A, Pletnikova O, O'Brien R, Yang A, Troncoso J, Legido-Quigley C, **Thambisetty M**. Neurotransmitter Imbalance in the Brain and Alzheimer's Disease Pathology. Journal of Alzheimer's Disease 72(1):35-43 (2019) PMID: pending
75. Isaacson RS, Hristov H, Saif N, Hackett K, Hendrix S, Melendez J, Safdieh J, Fink M, **Thambisetty M**, Sadek G, Bellara S, Lee P, Berkowitz C, Rahman A, Meléndez-Cabrero J, Caesar E, Cohen R, Lu PL, Dickson SP, Hwang MJ, Scheyer O, Mureb M, Schelke MW, Niotis K, Greer CE, Attia P, Mosconi L, Krikorian R. Individualized clinical management of patients at risk for Alzheimer's dementia. Alzheimer's and Dementia 15(12):1588-1602 (2019) PMID: [PMC6925647](#)
76. Tian Q, Chastan N, **Thambisetty M**, Resnick SM, Ferrucci L, Studenski SA. Bimanual Gesture Imitation Links to Cognition and Olfaction. Journal of the American Geriatric Society 67(12):2581-2586 (2019) PMID: pending
77. Mahajan UV, Varma VR, Griswold ME, Blackshear CT, An Y, Oommen AM, Varma S, Troncoso JC, Pletnikova O, O'Brien R, Hohman TJ, Legido-Quigley C, **Thambisetty M**. Dysregulation of multiple metabolic networks related to brain transmethylation and polyamine pathways in Alzheimer disease: A targeted metabolomic and transcriptomic study. PLOS Medicine 17(1):e1003012 (2020) PMID: [PMC6980402](#)
78. Roberts JA, Varma VR, Huang C-W, An Y, Oommen AM, Tanaka T, Ferrucci L, Elango P, Takebayashi T, Harada S, Iida M, **Thambisetty M**. Blood metabolite signature of metabolic syndrome implicates alterations in amino acid metabolism: findings from the Baltimore Longitudinal Study of Aging (BLSA) and the Tsuruoka Metabolomics Cohort Study (TMCS). International Journal of Molecular Sciences 21(4). pii: E1249 (2020) PMID: [PMC7072861](#)
79. Mahajan UV, Varma VR, Huang C-W, An Y, Tanaka T, Ferrucci L, Takebayashi T, Harada S, Iida M, Legido-Quigley C, **Thambisetty M**. Blood Metabolite Signatures of Metabolic Syndrome in Two Cross-Cultural Older Adult Cohorts. International Journal of Molecular Sciences 21(4). pii: E1324 (2020) PMID: [PMC7072935](#)
80. Johnson ECB, Dammer EB, Duong DM, Ping L, Zhou M, Yin L, Higginbotham LA, Guajardo A, White B, Troncoso JC, **Thambisetty M**, Montine TJ, Lee EB, Trojanowski JQ, Beach TJ, Reiman EM, Haroutunian V, Wang M, Schadt E, Zhang B, Dickson DW, Ertekin-Taner N, Golde TE, Petyuk VA, De Jager PL, Bennett DA, Wingo TS, Rangaraju S, Hajjar I, Shulman JM, Lah JJ, Levey AI, Seyfried NT. Large-scale proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nature Medicine 26(5):769-780 (2020) PMID: [PMC7405761](#)

81. Wingo AP, Fan W, Duong DM, Gerasimov ES, Dammer EB, Liu Y, HarerimanaN, White B, **Thambisetty M**, Troncoso JC, Kim N, Schneider JA, Hajjar IM, Lah JJ, Bennett DA, Seyfried NT, Levey AI, Wingo TS: Shared proteomic effects of cerebral atherosclerosis and Alzheimer's disease on the human brain. Nature Neuroscience 23(8):1034 (2020) PMID:PMC7269838
82. Chuang Y-F, Varma VR, An Y, Tanaka T, Davatzikos C, Resnick SM **Thambisetty M**. Interaction between APOE and Butyrylcholinesterase (BCHE) genes on risk of Alzheimer's disease in a prospective cohort study. Journal of Alzheimer's Disease 75(2):417-427 (2020) PMID: pending
83. Tanaka T, Lavery R, Varma VR, Fantoni G, Colpo M, **Thambisetty M**, Cheung F, Resnick SM, Bennett DA, Biancotto A, Stefania Bandinelli S, Ferrucci L Plasma proteomic signatures predict dementia and cognitive impairment. Alzheimer's & Dementia: Translational Research & Clinical Interventions 6(1):e12018 (2020) PMID:PMC7210784
84. Demarest TG, Varma V, Estrada D, Babbar M, Basu S, Mahajan U, Moaddell RA, Croteau DL, **Thambisetty M**, Mattson MP, Bohr VA (2020) Biological sex and DNA repair deficiency drive Alzheimer's disease via systemic metabolic remodeling and brain mitochondrial dysfunction. Acta Neuropathologica 140(1):25-47 (2020) PMID:PMC7537767
85. Desai RJ, Varma V, Gerhard T, Segal J, Mahesri M, Chin K, Nonnenmacher E, Gabbeta A, Mammen AM, Varma S, Horton DM, Kim SC, Schneeweiss S, **Thambisetty M** (2020). Targeting abnormal metabolism in Alzheimer's disease: The Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study. Alzheimer's & Dementia: Translational Research & Clinical Interventions 6(1):e12095 (2020) PMID:PMC7690721
86. Varma VR, Wang Y, An Y, Varma S, Bilgel M, Doshi J, Legido-Quigley C, Delgado JC, Oommen AM, Roberts JA, Wong DF, Davatzikos C, Resnick SM, Troncoso JC, Pletnikova O, O'Brien R, Hak E, Baak BN, Pfeiffer R, Baloni P, Mohmoudiandehkordi S, Nho K, Kaddurah-Daouk R, Bennett DA, Gadalla SM, **Thambisetty M**. Bile acid synthesis, modulation, and dementia: A metabolomic, transcriptomic, and pharmacoepidemiologic study. PLOS Medicine 18(5):e1003615 (2021) PMID: PMC8158920
87. Varma VR, Büşra Lüleci H, Oommen AM, Varma S, Blackshear CT, Griswold ME, An Y, Roberts JA, O'Brien R, Pletnikova O, Troncoso JC, Bennett DA, Çakır T, Legido-Quigley C, **Thambisetty M**. Abnormal brain cholesterol homeostasis in Alzheimer's disease-a targeted metabolomic and transcriptomic study. NPJ Aging and Mechanisms of Disease 7(1):11 (2021) PMID: PMC8169871
88. Ashton NJ, Janelidze S, Al Khleifat A, Leuzy A, van der Ende EL, Karikari TK, Benedet AL, Pascoal TA, Lleó A, Parnetti L, Galimberti D, Bonanni L, Pilotto A, Padovani A, Lycke

- J, Novakova L, Axelsson M, Velayudhan L, Rabinovici GD, Miller B, Pariante C, Nikkheslat N, Resnick SM, **Thambisetty M**, Schöll M, Fernández-Eulate G, Gil-Bea FJ, López de Munain A, Al-Chalabi A, Rosa-Neto P, Strydom A, Svenningsson P, Stomrud E, Santillo A, Aarsland D, van Swieten JC, Palmqvist S, Zetterberg H, Blennow K, Hye A, Hansson O. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nature Communications. 12(1):3400 (2021) PMID: PMC8185001
89. Munk R, Anerillas C, Rossi M, Tsitsipatis D, Martindale JL, Herman AB, Yang JH, Roberts JA, Varma VR, Pandey PR, **Thambisetty M**, Gorospe M, Abdelmohsen K. Acid ceramidase promotes senescent cell survival. Aging 13(12):15750-15769 (2021) PMID: PMC8266329
90. Jackson A. Roberts, Vijay R. Varma, Yang An, Sudhir Varma, Julián Candia, Giovanna Fantoni, Ruin Moaddel, Mohammed Khadeer, Jacqueline Lovett, Toshiko Tanaka, Olga Pletnikova, Juan C. Troncoso, David A. Bennett, Marilyn S. Albert, Kaiwen Yu, Mingming Niu, Vahram Haroutunian, Bin Zhang, Junmin Peng, Susan M. Resnick, Luigi Ferrucci, **Madhav Thambisetty**. A Brain Proteomic Signature of Incipient Alzheimer's Disease in Young *APOE* ϵ 4 Carriers identifies novel drug targets. Science Advances 12;7(46):eabi8178 (2021) PMID: PMC8580310
91. Cochran KR, Veeraraghavan K, Kundu G, Mazan-Mamczarz K, Coletta C, **Thambisetty M**, Gorospe M, De S. Systematic identification of circRNAs in Alzheimer's Disease. Aging 18;12(8):1258 (2021) PMID: PMC8391980
92. Desai RJ, Varma V, Gerhard T, Segal J, Mahesri M, Chin K, Horton DM, Kim SC, Schneeweiss S, **Thambisetty M**. Comparative risk of Alzheimer's disease and related dementia among Medicare beneficiaries with rheumatoid arthritis treated with targeted disease modifying antirheumatic agents JAMA Network Open (2022) PMID: PMC8994126
93. Trumpff, C., Owusu-Ansah, E., Klein, H.U., Lee, A., Petyuk, V., Wingo, T.S., Wingo, A.P., **Thambisetty, M.**, Ferrucci, L., Seyfried, N.T., Bennett, D.A., De Jager, P.L., Picard, M. Mitochondrial Respiratory Chain Protein Co-Regulation in the Human Brain. Heliyon 8(5):e09353 (2022) PMID: PMC9118667
94. Tang B, Wang Y, Jiang X, **Thambisetty M**, Ferrucci L, Johnell K, Hägg S. Genetic Variation in Targets of Anti-diabetic Drugs and Alzheimer Disease Risk: A Mendelian Randomization Study. Neurology. 2022 [In press] PMID: Pending
95. Desai RJ, Mahesri M, Lee SB, Varma VR, Loeffler T, Schilcher I, Gerhard T, Segal JB, Ritchey ME, Horton DB, Kim SC, Schneeweiss S and **Thambisetty M**. No association between initiation of phosphodiesterase-5 inhibitors and risk of incident Alzheimer's disease

and related dementia: results from the Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study. Brain Communications. 2022 [In press] PMID: Pending

Review articles

96. **Thambisetty M**, Newman N. Diagnosis and management of MELAS. Expert Review of Molecular Diagnostics. 4(5): 89-102, (2004) PMID:15347257
97. Simon Lovestone, Andreas Guentert, Abdul Hye, Lynham S, **Thambisetty M**, Ward M. Proteomics of Alzheimer's Disease - understanding mechanisms, seeking biomarkers. Expert Review of Proteomics. 4(2): 227-238, (2007) PMID: pending
98. **Thambisetty M** and Lovestone S. Blood-based biomarkers of Alzheimer's disease: challenging but feasible. Biomarkers in Medicine. 4(1): 65-79, (2010) PMID: PMC2863057
99. Wai M, Wong K, Braidy N, Poljak A, Pickford R, **Thambisetty M**, Sachdev P. Dysregulation of lipids in Alzheimer's disease and their role as potential biomarkers. Alzheimer's and Dementia. 13(7):810-827 (2017) PMID: pending

Editorial articles and correspondence

100. Lovestone S and **Thambisetty M**. Biomarkers for Alzheimer's disease trials – biomarkers for what? A discussion paper. Journal of Nutrition, Health and Aging 13(4):334-6, (2009) PMID: pending
101. **Thambisetty M**. Do extracellular chaperone proteins in plasma have potential as Alzheimer's disease biomarkers? Biomarkers in Medicine. 4(6): 831-834, (2010) (invited editorial) PMID: pending
102. **Thambisetty M** and Ferrucci L. Soluble interleukin-6 receptor levels and risk of dementia: one more signpost on a long road ahead. Journal of the American Geriatrics Society. 62:772–774 (2014) (invited editorial) PMID: PMC4577022
103. **Thambisetty M**, Casanova R, Varma S, Legido-Quigley C. Peril beyond the winner's curse-A small sample size is the bane of biomarker discovery. Alzheimer's and Dementia. 13(5):606-607 (2017) PMID: pending
104. Seddighi S, Varma VR, **Thambisetty M**. Alpha2-macroglobulin in Alzheimer's disease: new roles for an old chaperone. Biomarkers in Medicine. 12(4):311-314 (2018) (invited editorial) PMID: PMC5967355

105. **Thambisetty M.** Plasma apolipoprotein-E levels and risk of dementia: You are the company you keep. JAMA Network Open. 3(7):e209501 (2020) (invited editorial) PMID: pending
106. **Thambisetty M,** Howard R, Glymour MM, Schneider LS. Alzheimer's drugs: does reducing amyloid work? Science 374(6567):544-545 (2021)

Book chapters

1. **Madhav Thambisetty** Alzheimer's Disease: basic concepts and current research. In Human Brain: essays on awareness. Ed: T.Ramakrishna, Calicut University Press (2001)
2. **Madhav Thambisetty,** James Lah, Allan Levey. Dementia: In Medical Management of the Surgical Patient, Eds: Michael Lubin and Kenneth Walker, Cambridge University Press (2006)
3. **Madhav Thambisetty,** Nestor Gálvez, Thyagarajan Subramanian. Advances in the Treatment of Dementia: In Imaging of Neurodegenerative Disorders, Ed: Sangam Kanekar, Thieme Publishers (2016)
4. Vijay Varma, Yi-Fang Chuang, **Madhav Thambisetty.** Neuroimaging and fluid biomarkers of Alzheimer's disease: implications for definition, diagnosis, and treatment. Oxford Textbook of Neurologic and Neuropsychiatric Epidemiology, Edited by Carol Brayne, Valery Feigin, Lenore Launer, and Giancarlo Logroscino, Oxford University Press (OUP) (2020)
5. Hatice Büşra Lüleci, Dilara Uzuner, Tunahan Çakır, **Madhav Thambisetty** Computational approaches to assess abnormal metabolism in Alzheimer's Disease using transcriptomics. Methods in Molecular Biology, Springer Protocols, Edited by Jerold Chun, Humana Press (2021) (in press)
6. Jackson Roberts, Vijay Varma, **Madhav Thambisetty** Metabolomics of Dementia: Understanding the Metabolic Underpinnings of Disease. Dementia: A Global Approach, 2nd edition, Edited by ES Krishnamoorthy and J. Cummings. Cambridge University Press (CUP) (in press)